October 14, 2021 10:54 AM EDT
News Briefing

Ex­elix­is, Storm join up in col­lab­o­ra­tion and li­cense agree­ment; Teligent files for bank­rupt­cy

Paul Schloesser

Associate Editor

Ex­elix­is and RNA-fo­cused biotech Storm Ther­a­peu­tics en­tered in­to an ex­clu­sive col­lab­o­ra­tion and li­cense agree­ment, the com­pa­nies joint­ly an­nounced to­day.

The deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times